Pharmacare News Bulletins

Nova Scotia Pharmacare

Pharmacare News Bulletins

The Pharmacare News Bulletins, which are mailed to pharmacies and physicians, are listed below. They are an important source of information as they provide timely information on recent changes to the Pharmacare Programs.

Please continue to refer to the Pharmacare News Bulletins to stay current with Formulary and Pharmacare Program updates.

Pharmacare News: Pharmacists Edition

Latest Issues

December Bulletin Vol. 19 – 10
New Pharmacare Tariff and Pharmacy Service Agreements

December Bulletin Vol. 19 – 09
New Exception Status Benefits: Trelegy Ellipta (fluticasone furoate/ umeclidinium/vilanterol), Caprelsa (vandetanib), Cathflo (alteplase)

October Bulletin Vol. 19 – 08
New Exception Status Benefits: Kisqali (ribociclib), Tagrisso (osimertinib) Criteria Updates : Actemra (tocilizumab), Stivarga (regorafenib)

September Bulletin Vol. 19 – 07
New Exception Status Benefits: Spinraza (nusinersen), Venclexta (venetoclax), Akynzeo (netupitant/palonosetron), Alecensaro (alectinib), Fasenra (benralizumab), Renflexis (infliximab), Rexulti (brexpiprazole), Zykadia (ceritinib) Criteria Updates: Emend (aprepitant), Nucala (mepolizumab)

August Bulletin Vol. 19 – 06
New Exception Status Benefits: Galafold (migalastat), Cycle-Nitisinone and Orfadin (nitisinone), Revestive (teduglutide), Dysport Therapeutic (abobotulinum toxin A), Rydapt (midostaurin)

June Bulletin Vol. 19 – 05
New Exception Status Benefits: Lixiana (edoxaban)

May Bulletin Vol. 19 – 04
New Exception Status Benefits: Siliq (brodalumab), Maviret (glecaprevir/pibrentasvir)

May Bulletin Vol. 19 – 03
New Exception Status Benefits: Movapo (apomorphine), Enstilar (calcipotriol/betamethasone diproprionate), Ilaris (canakinumab), Praluent (alirocumab), Repatha (evolocumab)

April Bulletin Vol. 19 – 02
New Exception Status Benefits: Brivlera (brivaracetam), Entresto (sacubitril/valsartan), Lynparza (olaparib), Pheburane (sodium phenylbutyrate)

February Bulletin Vol. 19 – 01
New Exception Status Benefits: Procysbi (cysteamine bitartrate), Nucala (mepolizumab), Ocaliva (obeticholic acid), Ravicti (glycerol phenylbutyrate), Taltz (ixekizumab) Criteria Update: Cimzia (certolizumab pegol), Enbrel (etanercept), Humira (adalimumab), Inflectra and Remicade (infliximab), Simponi (golimumab)

Pharmacare News: Physicians Edition

Latest Issue

December Bulletin Vol. 19 – 09
New Exception Status Benefits: Trelegy Ellipta (fluticasone furoate/ umeclidinium/vilanterol), Caprelsa (vandetanib), Cathflo (alteplase)

October Bulletin Vol. 19 – 08
New Exception Status Benefits: Kisqali (ribociclib), Tagrisso (osimertinib) Criteria Updates : Actemra (tocilizumab), Stivarga (regorafenib)

September Bulletin Vol. 19 – 07
New Exception Status Benefits: Spinraza (nusinersen), Venclexta (venetoclax), Akynzeo (netupitant/palonosetron), Alecensaro (alectinib), Fasenra (benralizumab), Renflexis (infliximab), Rexulti (brexpiprazole), Zykadia (ceritinib) Criteria Updates: Emend (aprepitant), Nucala (mepolizumab)

August Bulletin Vol. 19 – 06
New Exception Status Benefits: Galafold (migalastat), Cycle-Nitisinone and Orfadin (nitisinone), Revestive (teduglutide), Dysport Therapeutic (abobotulinum toxin A), Rydapt (midostaurin)

June Bulletin Vol. 19 – 05
New Exception Status Benefits: Lixiana (edoxaban)

May Bulletin Vol. 19 – 04
New Exception Status Benefits: Siliq (brodalumab), Maviret (glecaprevir/pibrentasvir)

May Bulletin Vol. 19 – 03
New Exception Status Benefits: Movapo (apomorphine), Enstilar (calcipotriol /betamethasone diproprionate), Ilaris (canakinumab), Praluent (alirocumab), Repatha (evolocumab)

April Bulletin Vol. 19 – 02
New Exception Status Benefits: Brivlera (brivaracetam), Entresto (sacubitril/valsartan), Lynparza (olaparib), Pheburane (sodium phenylbutyrate)

February Bulletin Vol. 19 – 01
New Exception Status Benefits: Procysbi (cysteamine bitartrate), Nucala (mepolizumab), Ocaliva (obeticholic acid), Ravicti (glycerol phenylbutyrate), Taltz (ixekizumab) Criteria Update: Cimzia (certolizumab pegol), Enbrel (etanercept), Humira (adalimumab), Inflectra and Remicade (infliximab), Simponi (golimumab)